Mellow Hope completes MEVAC-A tender for Bangladesh

HTDS company is pleased to announce that its China based operating subsidiary Mellow Hope has successfully completed and delivered on its tender for Mevac-A for the country of Bangladesh.

In developing countries, over 11 million children aged less than five years die each year, and nearly three quarters of these deaths result from infectious diseases. The World Health Organization (WHO) estimates that the death of at least four million of these children is linked to their lack of access to vaccines. Vaccines are highly effective against childhood diseases preventing an estimated three million deaths a year.

Every year Mellow Hope attends the government tender business of Hepatitis A Vaccine in Bangladesh. By virtue of Mellow Hope's high quality and competitive price, Mellow Hope's Hepatitis A Vaccine (MEVAC-A) has won the tenders in the last three consecutive years.

For 2009, Mellow Hope scheduled, and secured, and shipped the order. Mellow Hope is now preparing to participate for the 2010 tender.

As Mellow Hope has established a very solid foundation, strong track record and brand recognition in this region it is confident that it will also be successful with its 2010 tender as well.

In other company news, the company has completed certain filings on Pink Sheets, and brings attention with this release to those matters. One of the filings is the engagement letter of an SEC auditor as the company gears to complete its audit and become a reporting issuer. The second filing deals with certain activities of "oversold" and "sell only" campaign which affected HTDS. These are just one of many steps the company intends to take to protect its and its shareholders' interests.

Shortly the company will provide its followers with an update of behind the scenes measures and steps it is taking to address this issue. The company remains optimistic that just some the steps and measures it took will start to take effect and start trickling down as the market correct itself and the short covering begins.

Numerous updates to follow shortly on IP progress, the joint venture with the North American pharmaceutical company and other previously announced business matters.

http://www.htdsmedical.com/